Cargando…

In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response

INTRODUCTION: Modern accelerators have the “flattening filter-free” (FFF) technique to deliver RT with a moderate high-dose rate, currently used in limited clinical indications. No scientifically established data are currently available on the possible effects of this high dose rate on the anti-tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurent, P.A., Kownacka, A., Boidot, R., Richard, C., Limagne, E., Morgand, V., Froidurot, L., Bonin, C., Aubignac, L., Ghiringhelli, F., Créhange, G., Mirjolet, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415635/
https://www.ncbi.nlm.nih.gov/pubmed/32793819
http://dx.doi.org/10.1016/j.ctro.2020.07.004
_version_ 1783569188060659712
author Laurent, P.A.
Kownacka, A.
Boidot, R.
Richard, C.
Limagne, E.
Morgand, V.
Froidurot, L.
Bonin, C.
Aubignac, L.
Ghiringhelli, F.
Créhange, G.
Mirjolet, C.
author_facet Laurent, P.A.
Kownacka, A.
Boidot, R.
Richard, C.
Limagne, E.
Morgand, V.
Froidurot, L.
Bonin, C.
Aubignac, L.
Ghiringhelli, F.
Créhange, G.
Mirjolet, C.
author_sort Laurent, P.A.
collection PubMed
description INTRODUCTION: Modern accelerators have the “flattening filter-free” (FFF) technique to deliver RT with a moderate high-dose rate, currently used in limited clinical indications. No scientifically established data are currently available on the possible effects of this high dose rate on the anti-tumor immune response. We therefore propose here to study these effects in a preclinical CT26 murine colorectal tumor model. MATERIAL AND METHODS: In-vitro, CT26 cells were irradiated on a Varian TrueBeam® linac at 3 different dose rates (4; 12 or 24 Gy/min) using the FFF mode. Activation of the anti-tumor immune response was evaluated by the analysis of induction of genes of the type I interferon pathway by RT-qPCR, and by the study of the induction of immunogenic death biomarkers. In-vivo, an efficacy study of RT delivering 16.5 Gy at 2 different dose rates was performed in immunocompetent Balb/c mice carrying CT26 syngeneic tumors, as well as an immunomonitoring analysed by flow cytometry and a transcriptomic analysis using RNA sequencing. Statistical analyzes were performed using non-parametric tests. RESULTS: In-vitro, no significant influence of an increase in FFF dose rate was shown for the induction of genes of the type I interferon pathway as well as for the studied immunogenic death markers (HMGB1 secretion). In-vivo, no difference in terms of tumor growth retardation between the 2 dose rates used was demonstrated, as well as for the composition of immune cell infiltrates within tumor microenvironment and the expression of immune checkpoints in immunomonitoring and RNAseq. CONCLUSION: In this study involving the CT26 model, no influence of a moderate high dose rate in FFF technique on the anti-tumor immune response was demonstrated, which would make studies of associations between RT and checkpoint inhibitors fit with this technique of RT. However, further explorations using other cellular models seem to be of interest.
format Online
Article
Text
id pubmed-7415635
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74156352020-08-12 In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response Laurent, P.A. Kownacka, A. Boidot, R. Richard, C. Limagne, E. Morgand, V. Froidurot, L. Bonin, C. Aubignac, L. Ghiringhelli, F. Créhange, G. Mirjolet, C. Clin Transl Radiat Oncol Article INTRODUCTION: Modern accelerators have the “flattening filter-free” (FFF) technique to deliver RT with a moderate high-dose rate, currently used in limited clinical indications. No scientifically established data are currently available on the possible effects of this high dose rate on the anti-tumor immune response. We therefore propose here to study these effects in a preclinical CT26 murine colorectal tumor model. MATERIAL AND METHODS: In-vitro, CT26 cells were irradiated on a Varian TrueBeam® linac at 3 different dose rates (4; 12 or 24 Gy/min) using the FFF mode. Activation of the anti-tumor immune response was evaluated by the analysis of induction of genes of the type I interferon pathway by RT-qPCR, and by the study of the induction of immunogenic death biomarkers. In-vivo, an efficacy study of RT delivering 16.5 Gy at 2 different dose rates was performed in immunocompetent Balb/c mice carrying CT26 syngeneic tumors, as well as an immunomonitoring analysed by flow cytometry and a transcriptomic analysis using RNA sequencing. Statistical analyzes were performed using non-parametric tests. RESULTS: In-vitro, no significant influence of an increase in FFF dose rate was shown for the induction of genes of the type I interferon pathway as well as for the studied immunogenic death markers (HMGB1 secretion). In-vivo, no difference in terms of tumor growth retardation between the 2 dose rates used was demonstrated, as well as for the composition of immune cell infiltrates within tumor microenvironment and the expression of immune checkpoints in immunomonitoring and RNAseq. CONCLUSION: In this study involving the CT26 model, no influence of a moderate high dose rate in FFF technique on the anti-tumor immune response was demonstrated, which would make studies of associations between RT and checkpoint inhibitors fit with this technique of RT. However, further explorations using other cellular models seem to be of interest. Elsevier 2020-07-31 /pmc/articles/PMC7415635/ /pubmed/32793819 http://dx.doi.org/10.1016/j.ctro.2020.07.004 Text en © 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Laurent, P.A.
Kownacka, A.
Boidot, R.
Richard, C.
Limagne, E.
Morgand, V.
Froidurot, L.
Bonin, C.
Aubignac, L.
Ghiringhelli, F.
Créhange, G.
Mirjolet, C.
In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title_full In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title_fullStr In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title_full_unstemmed In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title_short In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
title_sort in-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415635/
https://www.ncbi.nlm.nih.gov/pubmed/32793819
http://dx.doi.org/10.1016/j.ctro.2020.07.004
work_keys_str_mv AT laurentpa invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT kownackaa invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT boidotr invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT richardc invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT limagnee invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT morgandv invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT froidurotl invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT boninc invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT aubignacl invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT ghiringhellif invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT crehangeg invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse
AT mirjoletc invivoandinvitroimpactofhighdoserateradiotherapyusingflatteningfilterfreebeamsontheantitumorimmuneresponse